Citrus is recognized as one of the most healthful components of the human diet. Much of the contribution of citrus in human health and nutrition is attributed to secondary metabolites present in the fruit including antioxidants, (ascorbic acid, flavanones, simple phenolics, carotenoids), folate and pectin.
From 2006 through 2009 the company undertook extensive documented citrus fruit studies with Sunkist growers at the fruit juice processing facilities in Ontario and Tipton, California to recover pectin, bioflavonoids, limonoids and limonene. Scientific validation was undertaken by USDA and Chromadex Inc. These investigations included considerable research of Sunkist production of FDA pharmaceutical extracts during the 1950 -1960’s of citrus bioflavonoids, limonoids, pectin, limonene and vitamin C. Furthermore, 104 Sunkist clinical publications on citrus bioflavonoids delivered conclusive evidence of citrus bioflavonoid efficacy in blood, vascular and capillary studies.
Based on these findings, the company second phase project is to process lemon fruits during the period the tea business is dormant and to recover a number of specific botanical extracts as active ingredients for
THE TREATMENT OF INFLAMMATORY CONDITIONS WITH CITRUS BIOFLAVONOIDS
A total of eleven studies were reviewed on the use of citrus bioflavonoids (Hesperidin) and ascorbic acid in the treatment of upper respiratory infections. Clinical trials Saylor (1956) with ninety nine patients with allergic and vasomotor rhinitis, (which so closely resembles the common cold with it nasal symptoms) observed complete or partial relief from 69% using Hesperidin, Chalcone and Sodium in daily divided doses.
WL Macon. Journal of Industry, Medicine and Surgery November 1956. A total of one hundred and twenty one persons who met rigid qualifications as having a common cold were studied with sixty two receiving a combination of lemon-orange flavonate glycoside, and ascorbic acid; and the other fifty nine receiving aspirin, phenacetin and caffeine, a well known palliative for the cold.
A total of forty six patients (74.2%) reported on the second day of taking the medication that they achieved complete or substantial relief when taking the bioflavonoid combination. In comparison only 30% (50.9%) taking ACP’s, the best known palliative obtained similar relief.